What is it about?
Aggregation of amyloidos is a pathological hallmark of neurodegenerative diseases, most of which are affected by multiple disease-causing amyloids and other biomolecules. Here we overview not only the cross-seeding or cross-inhibition of amyloidosis but the interplay of amyloids with nucleic acids.
Featured Image
Photo by National Cancer Institute on Unsplash
Why is it important?
The emerging role of interactions of amyloid coaggregates with biomolecules are recently featured in the understanding of neurodegenerative diseases at a molecular level. This is the first report of comprehensive review of amyloid coaggregates from the perspective of their interaction with cytosolic or nuclear biomolecules, not limiting to inter-amyloid interaction, and potential overlap among neurodegenerative diseases.
Perspectives
We are aiming for the rationale molecular design of anti-amyloid drugs based on the association of amyloid coaggregates with biomolecules in neurodegeneration. To achieve this, structural analysis for supramolecular behavior and dynamic capture of metastable amyloid coaggregates are needed, and thus aggregation inhibitors harboring dual inhibition activities against different pairs of coaggregates, and antagonistic nucleic acid medicines such as nucleic acid aptamers will be ones of reasonable options.
Dr. Kazuma Murakami
Kyoto University
Read the Original
This page is a summary of: Interactions of amyloid coaggregates with biomolecules and its relevance to neurodegeneration, The FASEB Journal, August 2022, Wiley,
DOI: 10.1096/fj.202200235r.
You can read the full text:
Contributors
The following have contributed to this page
